Figure 5.

Protective effect of DS‐5272 and NFκB signaling in vitro. HEK 293 cells were cultured with various concentration of cisplatin, with or without DS‐5272. (A) Cytotoxicity was analyzed by lactate dehydrogenase (LDH) release assay 24 hours after cisplatin treatment. (B) NFκB p65 transcriptional activity was analyzed by NFκB p65 Transcription Factor Assay Kit 12 hours after cisplatin treatment. Negative: negative control (without any nuclear extract), positive: positive control (provided in Kit), positive+competitor: positive control and NFκB p65 specific competitor (both were provided in Kit) Each assay was performed five times. *P < 0.05 cisplatin 0 μmol/L vs cisplatin 50, 100, or 200 μmol/L; #P < 0.05 DS‐5272 0 μmol/L vs 5 or 10 μmol/L